Attached files
| file | filename |
|---|---|
| EX-31.2 - CERTIFICATION - Hoth Therapeutics, Inc. | f10k2019ex31-2_hoththera.htm |
| EX-31.1 - CERTIFICATION - Hoth Therapeutics, Inc. | f10k2019ex31-1_hoththera.htm |
| EX-23.1 - CONSENT OF WITHUMSMITH+BROWN, PC - Hoth Therapeutics, Inc. | f10k2019ex23-1_hoththera.htm |
| EX-21.1 - SUBSIDIARIES OF THE REGISTRANT - Hoth Therapeutics, Inc. | f10k2019ex21-1_hoththera.htm |
| EX-10.22 - LICENSE AGREEMENT WITH NORTH CAROLINA STATE UNIVERSITY DATED NOVEMBER 20, 2019 - Hoth Therapeutics, Inc. | f10k2019ex10-22_hoththerap.htm |
| EX-10.9 - RENEWAL AGREEMENT WITH REGUS DATED MAY 2, 2019 - Hoth Therapeutics, Inc. | f10k2019ex10-9_hoththera.htm |
| 10-K - ANNUAL REPORT - Hoth Therapeutics, Inc. | f10k2019_hoththerapeutics.htm |
Exhibit 32.1
Statement of Chief Executive Officer
and Chief Financial Officer
Pursuant to Section 1350 of Title 18 of the United States Code
Pursuant to Section 1350 of Title 18 of the United States Code as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, Robb Knie and David Briones, the Chief Executive Officer and Chief Financial Officer, respectively, of Hoth Therapeutics, Inc. (the “Company”), hereby certify that based on the undersigned’s knowledge:
| 1. | The Company’s Annual Report on Form 10-K for the period ended December 31, 2019 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| 2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| Date: March 2, 2020 | /s/ Robb Knie |
| Robb Knie | |
| Chief Executive Officer and President | |
| (Principal Executive Officer) | |
| Date: March 2, 2020 | /s/ David Briones |
| David Briones | |
| Chief Financial Officer | |
| (Principal Financial and Accounting Officer) |